Endoscopy Devices Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Endoscopy Devices Market Trends and Insights

Rising Global Incidence of Gastrointestinal & Colorectal Cancers Driving Screening Demand

Colorectal cancer cases among U.S. adults aged 20-49 increased 9% between 2020 and 2024, prompting payers to broaden screening eligibility to younger cohorts^{[1]American Cancer Society, “Colorectal Cancer Statistics 2024,” cancer.org}. Endoscopy fleets therefore require faster refresh cycles, with high-volume centers acquiring high-definition (HD) colonoscopes that better visualize flat or depressed lesions responsible for 30% of interval cancers. Japan and South Korea illustrate the effect of mandatory screening: per-capita endoscope utilization runs three to four times higher than in Western systems, demonstrating the procedure volume that emerging Chinese and Indian programs could unleash. The World Health Organization’s 2024 cancer outlook projects a 47% rise in global cancer incidence by 2040, spotlighting gastrointestinal malignancies as the largest absolute increase. Regulators are also tightening quality standards; updated ISO 13485 audits link device performance directly to documented cancer-detection rates, raising the entry hurdle for new vendors.

Widespread Shift Toward Minimally Invasive Procedures Across Surgical Specialties

Minimally invasive techniques now represent 72% of elective abdominal surgeries in the United States, up from 64% in 2020^{[2]Agency for Healthcare Research and Quality, “HCUP Trends 2024,” ahrq.gov}. Bariatric endoscopic sleeve gastroplasty volumes jumped 38% in 2024 as shortages of GLP-1 agonists steered patients from pharmacotherapy to procedural weight management. Orthopedic arthroscopy follows a similar trajectory, with 85% of U.S. meniscus repairs completed arthroscopically in 2024. Robotic bronchoscopy platforms such as Intuitive Surgical’s Ion, cleared in 2024, reached an 89% diagnostic yield for sub-2 cm lung nodules, underscoring how flexible-scope technology increasingly merges with robotics. This broad procedural pivot expands the endoscopy devices market well beyond gastroenterology, opening white-space opportunities for hybrid visualization systems that blend rigid-scope precision with flexible-scope reach.

Continuous Innovation in Endoscopy Visualization Enhancing Clinical Outcomes

Between 2024 and 2026, the FDA cleared 14 artificial-intelligence (AI) colonoscopy systems, each embedding real-time polyp-detection software that lifts adenoma detection rates by 8-12 percentage points. Fujifilm’s CAD EYE, integrated into the ELUXEO 8000 platform, uses linked-color imaging to highlight vascular patterns linked to neoplasia. Olympus’s EVIS X1 achieved 97% sensitivity for Barrett’s esophagus dysplasia in a 2024 multicenter trial, outperforming white-light endoscopy by 14 percentage points. Karl Storz’s IMAGE1 S 4K system provides 8.3-megapixel resolution that helps surgeons identify nerve bundles during laparoscopic prostatectomy, reducing incontinence by 18%. Capsule solutions are also advancing; Medtronic’s PillCam, cleared in 2024 for Crohn’s disease monitoring, offers a non-invasive alternative to repeat ileocolonoscopy. These innovations shorten average colonoscopy time from 28 minutes to 22 minutes, allowing centers to raise daily throughput without extra staff.

Expansion of Ambulatory Surgical Centers Boosting Outpatient Endoscopy Volumes

ASCs completed 9.2 million U.S. GI endoscopies in 2024, a 14% jump since 2020, after Medicare’s 2024 site-neutral payment rule equalized reimbursement with hospital outpatient departments. Removing colonoscopy from the inpatient-only list opened another 2.3 million annual procedures to ASCs. Colonoscopy now costs Medicare USD 1,068 in an ASC versus USD 1,783 in a hospital outpatient department, a 40% savings that commercial plans replicate through preferred ASC networks. Twelve states scrapped certificate-of-need barriers between 2024 and 2026, with Florida, Texas, and Arizona hosting 38% of new centers. Compact integrated towers such as Olympus’s EVIS X1 Compact meet the footprint and budget constraints of these facilities. Similar outpatient growth is emerging in Japan and Germany after payers in both countries approved stand-alone ambulatory endoscopy clinics in 2024.

High Capital & Lifecycle Maintenance Costs of Advanced Endoscopic Systems

A fully integrated 4K tower with AI software lists between USD 180,000 and USD 250,000, about 60% higher than standard-definition rigs—a hurdle for community hospitals and ASCs with thin margins. Automated endoscope reprocessors (AERs), mandated by FDA and CDC protocols, cost USD 40,000-75,000 apiece, while high-level disinfectants add USD 12-18 per scope cycle^{[3]Centers for Disease Control and Prevention, “HAI Outbreaks Linked to Endoscopes 2024,” cdc.gov}. Total annual ownership of a reusable colonoscope averages USD 2,800 when maintenance, servicing, and reprocessing are included. Disposable scopes eliminate reprocessing costs but introduce a USD 200-400 per-case expense, limiting viability to low-volume or high-infection-risk settings. Emerging-market budgets remain tight; typical Indian public hospitals earmark USD 25,000 per year for endoscopy equipment, adequate for only a single mid-tier flexible scope. Leasing models that bundle capital, maintenance, and consumables into per-procedure fees are growing in Europe but still cover less than 5% of installed systems.

Persistent Infection-Control Challenges and Heightened Regulatory Scrutiny

The FDA issued 12 separate flexible-scope contamination alerts from 2024 to 2026, including a Class I recall of Olympus’s TJF-Q190V duodenoscope after 18 confirmed carbapenem-resistant Enterobacteriaceae infections. The Centers for Disease Control and Prevention (CDC) connected 47 healthcare-associated outbreaks in 2024 to improper endoscope reprocessing, with duodenoscopes and echoendoscopes implicated in 68% of cases. New FDA rules obligate manufacturers to conduct post-market surveillance on all flexible scopes with reusable components. Europe’s Medical Device Regulation (MDR) upgraded flexible endoscopes from Class IIa to Class IIb in 2024, requiring clinical proof of reprocessing efficacy plus third-party audits. Compliance costs are rising: Olympus disclosed USD 120 million in incremental regulatory spending for 2024, while smaller firms are exiting the reusable-scope market entirely. Single-use adoption spiked after the FDA recommended disposable duodenoscopes for high-risk ERCP cases, pushing penetration to 22% of such procedures by late 2025.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Device Type: Visualization Leads Innovation Race

Visualization equipment expanded at an 8.25% CAGR between 2026 and 2031, the fastest among all device categories. The segment’s momentum reflects hospital demand for 4K and AI-ready towers like Olympus’s EVIS X1 and Fujifilm’s ELUXEO 8000, both cleared in 2024, which cut adenoma miss rates by up to 14 percentage points. Endoscopes retained 38.55% of 2025 revenue, with flexible variants dominating gastroenterology and pulmonology. Capsule endoscopes, led by Medtronic’s PillCam, carved a niche in small-bowel imaging and Crohn’s disease surveillance. Robotic-compatible visualization, exemplified by Intuitive’s Ion bronchoscope, blends flexible reach with robotic precision, underpinning 89% diagnostic yields in peripheral lung biopsies.

Manual instruments such as snares and forceps are commoditizing as Asian suppliers exert price pressure, yet high-margin digital visualization suites offset the squeeze. Karl Storz’s IMAGE1 S 4K system supports nerve-sparing prostatectomy, demonstrating the clinical lift associated with ultra-high resolution. As a result, visualization commanded the largest slice of incremental revenue in the endoscopy devices market. Hybrid 4K/HD portfolios cater to budget-sensitive geographies where reimbursement remains inadequate for premium hardware, extending the replacement opportunity curve.

By Application: Laparoscopy Surges on Robotic Adoption

Gastrointestinal endoscopy held a commanding 55.53% share in 2025, driven by more than 19 million annual colonoscopies in the United States alone. Yet laparoscopy clocked the swiftest growth at an 8.85% CAGR through 2031 as robotic platforms reduced surgeon fatigue and enabled single-port appendectomies and cholecystectomies. Intuitive Surgical’s da Vinci SP, cleared for transoral applications in 2024, illustrates the convergence of rigid and flexible modalities under a robotic umbrella. Pulmonology accelerates too: the U.S. Preventive Services Task Force’s 2024 guidelines expanded lung-cancer screening eligibility, adding 6.4 million candidates and fueling adoption of robotic bronchoscopy systems.

ENT, urology, and gynecology procedures continue to benefit from HD imaging upgrades, while neurology endoscopy gains attention for hydrocephalus management via single-burr-hole techniques. Orthopedics remains mature but innovates through augmented-reality overlays that guide ligament reconstruction, a feature Smith & Nephew commercialized in its 4K arthroscopy suite in 2024. The breadth of clinical indications ultimately broadens the total addressable endoscopy devices market, insulating revenue streams from single-specialty slowdowns.

By Usability: Single-Use Gains Despite Cost Premium

Single-use and disposable scopes are set to grow at a 10.87% CAGR, outpacing reusable platforms as infection-control mandates intensify. Ambu’s disposable bronchoscopes and duodenoscopes, cleared in 2024 and 2025, remove reprocessing workflows and slash turnaround time from 45 minutes to zero. Boston Scientific priced its EXALT Model D duodenoscope at USD 1,850, about 40% above reusable per-procedure costs but attractive for low-volume centers. 

Reusable systems still dominate because Olympus’s EVIS X1 delivers 1.25 million-pixel resolution that disposable rivals cannot yet match. Hybrid models such as Pentax’s single-use forceps paired with reusable scopes offer a middle path that contains infection risk without forfeiting image quality. Environmental pressure is the main counterweight, as disposable scopes generate 3.2 times more plastic waste per case.

By End-User: ASCs Capture Outpatient Migration

ASCs registered a 9.7% CAGR through 2031, the fastest among end-users, after Medicare’s 2024 reforms removed site-of-service payment gaps. Hospital and academic centers still accounted for 42.13% of 2025 revenue, retaining complex ERCP and endoscopic submucosal dissection cases that demand surgical backup. Specialty clinics proliferate in Japan and Germany, where 2024 reimbursement updates recognized standalone endoscopy centers. Private-equity consolidation among U.S. ASCs continues, with platforms like Surgery Partners acquiring 47 GI-focused centers in 2024 to negotiate 15-20% capital equipment discounts. In emerging markets, reimbursement hurdles still tether procedure volumes to hospital settings, slowing the outpatient shift.

Geographical Analysis

North America held 41.13% of 2025 revenue due to Medicare’s elimination of cost-sharing for screening colonoscopies in 2024, which expanded the screening pool by 19 million people. ASCs performed 9.2 million GI endoscopies in 2024, consolidating their role as the primary outpatient site. Canada’s pilot of AI-assisted colonoscopy in Ontario and British Columbia improved adenoma detection by 11%, a catalyst for countrywide rollout. Mexico broadened coverage to an additional 8.2 million beneficiaries through the Instituto Mexicano del Seguro Social in 2024.

Asia-Pacific will post the fastest regional expansion with an 8.51% CAGR through 2031. China’s National Healthcare Security Administration extended endoscopy reimbursements to 95% of urban residents in 2025, while India’s Ayushman Bharat added upper-GI screening for high-risk groups. Japan’s 2024 decision to pay for AI-assisted colonoscopy accelerated the domestic shift to CAD EYE-enabled platforms. Australia started reimbursing capsule endoscopy for Crohn’s disease and suspected small-bowel bleeding in 2024, enlarging its advanced imaging base.

Europe experienced steady uptake after the MDR took full effect in 2024, compelling hospitals to modernize to compliant platforms. Germany allowed screening colonoscopies in certified ambulatory centers, easing hospital bottlenecks. G-BA.DE. France reimbursed single-use duodenoscopes for high-risk ERCP in 2024. The United Kingdom’s National Health Service is piloting AI colonoscopy across 12 trusts, aiming to cut interval cancer by 15% by 2027.

The Middle East is scaling capacity under Saudi Arabia’s Vision 2030, which earmarked USD 1.2 billion for endoscopy infrastructure. Brazil’s public system added diagnostic endoscopy to its primary-care benefits in 2024, covering 140 million citizens. Argentina’s private insurers embraced therapeutic endoscopy coverage the same year, widening access to advanced procedures.

Regulatory Landscape

Regulation for endoscopy devices continues to tighten around quality systems, post-market surveillance, and validated cleaning and sterilization performance, influencing both reusable and single-use portfolios. In the United States, the FDA Quality Management System Regulation (QMSR) became effective in February 2026, incorporating ISO 13485:2016 concepts into 21 CFR 820 expectations and raising expectations for design controls and supplier management across endoscopy platforms and accessories. In 2026, FDA also advanced risk-based classification through Class II (special controls) determinations for several gastroenterology and urology device categories, including endoscopic suturing devices for altering gastric anatomy (May 2026), endoscopic light-projecting measuring devices (June 2026), and endoscopic traction devices (June 2026), which support faster access pathways while prescribing specific performance and labeling requirements.

In Europe, the Medical Device Regulation (MDR, EU 2017/745) continues to drive recertification and documentation upgrades, with legacy-device transition timelines extended to 2027/2028 depending on risk class. The European Commission updated the list of harmonised standards supporting MDR via Commission Implementing Decision (EU) 2026/193 (adopted 28 January 2026) and further updates published in the Official Journal of the European Union in June 2026, signaling active alignment to revised standards for areas such as biological evaluation and sterilization. For manufacturers selling visualization towers, reusable flexible endoscopes, and high-risk accessories in the EU, the compliance workload increases, and procurement places more emphasis on traceability and validated infection-control performance.

Market Opportunities and Future Outlook

Procurement is shifting from stand-alone scopes toward integrated, upgradeable imaging and workflow chains that match outpatient throughput and quality-reporting needs. That approach creates whitespace for portable, footprint-efficient systems and add-on modules aimed at improving detection and documentation. In the United States, the ambulatory migration is already visible, with ASCs performing 9.2 million GI endoscopies in 2024, and it continues to shape demand for compact towers and flexible financing.

In parallel, faster adoption of AI-enabled visualization is supported by regulatory momentum, with 14 AI colonoscopy systems cleared by the FDA between 2024 and 2026, alongside payer actions such as Medicare removing cost-sharing for screening colonoscopies in 2024 and Japan reimbursing AI-assisted colonoscopy in 2024. Infection-control scrutiny and the operational burden of reprocessing are also expanding the commercial runway for single-use scopes and validated accessory sets, particularly in high-risk procedures and lower-volume sites. Uptake of single-use duodenoscopes is already evident, with penetration reaching 22% of high-risk ERCP cases by late 2025 following FDA recommendations and repeated contamination alerts, while manufacturers broaden single-use offerings, including office and outpatient ENT rhinolaryngoscopes. On the innovation side, 2026 regulatory clearances for new endoscopy systems and processors, including multiple FDA 510(k) clearances across endoscopy platforms, plus clinical advances in therapeutic tools such as high-pressure injection knives reporting higher R0 resection rates in complex colorectal ESD, support a pipeline that ties improved clinical endpoints to efficiency gains and reinforces replacement cycles for visualization equipment and specialized operative devices.